TNYA - Tenaya Therapeutics, Inc. Stock Price and Quote

TNYA [NASD]

Index	-	P/E	-	EPS (ttm)	-2.79	Insider Own	0.30%	Shs Outstand	66.87M	Perf Week	-4.11%
Market Cap	178.65M	Forward P/E	-	EPS next Y	-2.49	Insider Trans	-	Shs Float	63.48M	Perf Month	-7.89%
Income	-123.70M	PEG	-	EPS next Q	-0.57	Inst Own	55.70%	Short Float / Ratio	1.42% / 2.45	Perf Quarter	45.92%
Sales	-	P/S	-	EPS this Y	32.70%	Inst Trans	-6.62%	Short Interest	0.90M	Perf Half Y	-15.03%
Book/sh	4.40	P/B	0.60	EPS next Y	8.80%	ROA	-47.40%	Target Price	21.50	Perf Year	-76.85%
Cash/sh	2.76	P/C	0.96	EPS next 5Y	-	ROE	-54.20%	52W Range	1.64 - 14.43	Perf YTD	33.58%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-81.39%	Beta	-
Dividend %	-	Quick Ratio	8.00	Sales past 5Y	-	Gross Margin	-	52W Low	63.72%	ATR	0.26
Employees	141	Current Ratio	8.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	47.15	Volatility	7.23% 9.93%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	3.90%	Profit Margin	-	Rel Volume	0.21	Prev Close	2.64
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 08 AMC	Payout	-	Avg Volume	366.75K	Price	2.68
Recom	1.90	SMA20	-6.58%	SMA50	-8.60%	SMA200	-23.26%	Volume	52,192	Change	1.70%

Jun-15-22

Initiated

H.C. Wainwright

Buy

$25

Mar-08-23 04:01PM	Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update GlobeNewswire -6.96%
Feb-07-23 05:17PM	Tenaya Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Jan-26-23 12:00PM	Tenaya Therapeutics, Inc. (TNYA) Upgraded to Buy: Here's What You Should Know Zacks
Jan-09-23 07:00AM	Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones GlobeNewswire
Dec-21-22 06:12AM	Insiders who placed huge bets on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) earlier this year would be disappointed with the 23% drop Simply Wall St.
04:30PM	Loading…
Dec-07-22 04:30PM	Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors GlobeNewswire
Dec-02-22 06:36PM	IRobot and Acrivon Stock See Action From Activist Investors Barrons.com
Nov-28-22 08:30AM	Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy GlobeNewswire +7.11%
Nov-24-22 05:54AM	Here's Why Tenaya Therapeutics (NASDAQ:TNYA) Must Use Its Cash Wisely Simply Wall St.
Nov-23-22 09:00AM	Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference GlobeNewswire
Nov-21-22 05:45PM	Tenaya Therapeutics Announces Closing of Public Offering GlobeNewswire
Nov-17-22 12:39AM	Tenaya Therapeutics Announces Pricing of Public Offering GlobeNewswire -21.63%
Nov-16-22 04:01PM	Tenaya Therapeutics Announces Proposed Public Offering GlobeNewswire +8.87%
Nov-10-22 04:05PM	Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update GlobeNewswire +6.81%
Nov-04-22 08:00AM	Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022 GlobeNewswire -17.87%
06:12AM	Loading…
Oct-14-22 06:12AM	Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) 17% loss last week hit both individual investors who own 40% as well as institutions Simply Wall St.
Oct-04-22 08:30AM	Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress GlobeNewswire
Sep-29-22 08:00AM	Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Societys 2022 Scientific Sessions GlobeNewswire -10.42%
07:45AM	Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences GlobeNewswire
Sep-26-22 09:21AM	10 Best Biotech Stocks Under $10 Insider Monkey
Sep-15-22 09:39AM	Harvard Universitys Latest Portfolio: 10 Best Biotech Stock Picks Insider Monkey
Sep-06-22 04:05PM	Tenaya Therapeutics to Participate in Upcoming September Investor Conferences GlobeNewswire -7.24%
08:00AM	Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction GlobeNewswire
Aug-16-22 09:55AM	Does Tenaya Therapeutics, Inc. (TNYA) Have the Potential to Rally 368% as Wall Street Analysts Expect? Zacks -7.50%
Aug-10-22 04:01PM	Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update GlobeNewswire
Jul-06-22 02:00PM	Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure GlobeNewswire
Jun-16-22 08:00AM	Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics Business Wire
May-20-22 08:30AM	Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference Business Wire +18.33%
May-11-22 04:09PM	Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Business Wire -12.00%
May-07-22 09:38AM	We're Not Very Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate Simply Wall St.
08:00AM	Loading…
May-03-22 08:00AM	Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform Capabilities at the American Society of Gene and Cell Therapy 25th Annual Meeting Business Wire
Apr-28-22 08:00AM	Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022 Business Wire +5.34%
Mar-24-22 08:30AM	Tenaya Therapeutics to Participate in Upcoming Investor Conferences Business Wire +12.51%
Mar-23-22 04:05PM	Tenaya Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Updates Business Wire -5.76%
Feb-08-22 12:01PM	Why Earnings Season Could Be Great for Tenaya Therapeutics (TNYA) Zacks
Feb-04-22 01:03PM	What Is The Ownership Structure Like For Tenaya Therapeutics, Inc. (NASDAQ:TNYA)? Simply Wall St. +7.56%
Jan-31-22 08:00AM	Tenaya Therapeutics to Participate in Upcoming Investor Conferences Business Wire +14.40%
Jan-10-22 08:00AM	Tenaya Therapeutics Provides 2022 Business Updates Business Wire -6.86%
Dec-23-21 12:38PM	Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ... GuruFocus.com
Dec-22-21 04:05PM	Tenaya Therapeutics Appoints Karah Parschauer, J.D., to Its Board of Directors and Joanna Auch as Senior Vice President of People and Culture Business Wire +8.98%
Dec-17-21 10:06AM	Harvard University Stock Portfolio: 8 Latest Stock Picks Insider Monkey
Nov-22-21 08:00AM	Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors Business Wire -8.27%
Nov-19-21 08:00AM	Tenaya Therapeutics to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference Business Wire
Nov-10-21 04:05PM	Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates Business Wire
Nov-05-21 08:36PM	Gene Therapy Is a Huge Opportunity. It Pays to be Patient. Barrons.com
03:30AM	Testing May Take Awhile, but Gene Therapy Is Poised to Tackle Mass Diseases Barrons.com
Nov-03-21 03:41PM	We're Not Very Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate Simply Wall St.
Oct-12-21 06:05PM	Tenaya Therapeutics to Present Preclinical Data on Its Gene Therapy Programs at the ESGCT 28th Annual Congress Business Wire -6.02%
Oct-08-21 12:42PM	Most of this year's flood of new Bay Area public companies are 'under water' American City Business Journals
Oct-04-21 10:54AM	Buy These 3 New Stocks Before They Jump Over 60%, Say Analysts TipRanks +5.78%
Sep-30-21 06:02PM	Tenaya Therapeutics to Participate in Upcoming Investor and Industry Conferences Business Wire
Sep-08-21 04:00PM	Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates Business Wire
Aug-31-21 08:00AM	Tenaya Therapeutics to Present at Morgan Stanley 19th Annual Global Healthcare Conference Business Wire -21.45%
Aug-03-21 04:05PM	Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares Business Wire
Jul-30-21 05:28PM	Dole Drops in IPO. 7 Biotechs Went Public, Too. Barrons.com
Jul-29-21 11:46PM	Tenaya Therapeutics Announces Pricing of Upsized Initial Public Offering Business Wire

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
COLUMN GROUP III GP, LP	10% Owner	Mar 10	Buy	2.60	6,779	17,596	11,377,053	Mar 14 04:12 PM
GOEDDEL DAVID V	Director	Mar 10	Buy	2.60	6,779	17,596	11,377,053	Mar 14 04:09 PM
COLUMN GROUP III GP, LP	10% Owner	Feb 08	Buy	2.60	1,500,000	3,900,000	11,370,274	Feb 10 04:32 PM
GOEDDEL DAVID V	Director	Feb 08	Buy	2.60	1,500,000	3,900,000	11,370,274	Feb 10 04:22 PM
COLUMN GROUP III GP, LP	10% Owner	Jan 19	Buy	2.50	69,739	174,201	9,870,274	Jan 23 04:25 PM
GOEDDEL DAVID V	Director	Jan 19	Buy	2.50	69,739	174,201	9,870,274	Jan 23 04:21 PM
GOEDDEL DAVID V	Director	Jan 18	Buy	2.52	135,688	341,432	9,800,535	Jan 19 04:13 PM
COLUMN GROUP III GP, LP	10% Owner	Jan 18	Buy	2.52	135,688	341,432	9,800,535	Jan 19 04:18 PM
COLUMN GROUP III GP, LP	10% Owner	Jan 17	Buy	2.49	49,463	123,395	9,664,847	Jan 19 04:18 PM
GOEDDEL DAVID V	Director	Jan 17	Buy	2.49	49,463	123,395	9,664,847	Jan 19 04:13 PM
COLUMN GROUP III GP, LP	10% Owner	Nov 21	Buy	2.60	9,615,384	24,999,998	9,615,384	Nov 23 04:12 PM
GOEDDEL DAVID V	Director	Nov 21	Buy	2.60	9,615,384	24,999,998	9,615,384	Nov 23 04:11 PM
Srivastava Deepak	Director	Nov 21	Buy	2.60	230,769	599,999	372,435	Dec 09 07:59 PM
Casdin Eli	Director	Nov 17	Buy	2.60	2,492,042	6,479,309	6,078,860	Nov 25 07:05 PM
Hoey Timothy	Chief Scientific Officer	Apr 26	Sale	10.13	1,353	13,706	198,646	Apr 28 07:57 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience